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Unravelling the molecular mechanisms that account for functional pleiotropy
is a major challenge for researchers in cytokine biology. Cytokine–receptor
cross-reactivity and shared signalling pathways are considered primary drivers
of cytokine pleiotropy. However, reports epitomized by studies of Jak-STAT
cytokine signalling identify interesting biochemical and epigenetic determi-
nants of transcription factor regulation that affect the delivery of signal-
dependent cytokine responses. Here, a regulatory interplay between STAT
transcription factors and their convergence to specific genomic enhancers sup-
port the fine-tuning of cytokine responses controlling host immunity, func-
tional identity, and tissue homeostasis and repair. In this review, we provide
an overview of the signalling networks that shape the way cells sense and
interpret cytokine cues. With an emphasis on the biology of interleukin-6, we
highlight the importance of these mechanisms to both physiological processes
and pathophysiological outcomes.
Keywords: arthritis; cytokine receptors; cytokines; epigenetics; inflammation;
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Interleukin (IL)-6 controls multiple phenotypic traits
that impact both immune effector functions and the
regulation of homeostatic processes. Although tradi-
tionally viewed as a pro-inflammatory cytokine
involved in disease progression, the biology of IL-6 is
complex contributing to metabolism, development, tis-
sue turnover and psychological well-being [1–8]. This
range of cytokine activities illustrates the context-
dependent nature of IL-6 signalling. How IL-6 acting
through a single receptor system elicits these diverse
biological outcomes remains unclear. So, what is the
evidence for IL-6 involvement in these processes?
The functional pleiotropy of IL-6 is typified by
observations made in patients lacking a functional
IL-6 receptor cassette or downstream signalling inter-
mediates, and children with anti-IL-6 autoantibodies
[9–15]. These individuals show altered humoral and
T-cell responses, eosinophilia, impaired acute phase
response, susceptibility to fungal infection, epidermal
afflictions including eczema and skin lesions sugges-
tive of connective tissue defects [9–14]. Similar phe-
notypic traits are also seen in patients with
mutations in STAT1 and STAT3, the principle
downstream transcription factors of IL-6 signalling
[9,16,17]. Other examples have arisen from documen-
tation of the clinical efficacy of biological drugs and
small molecule inhibitors that block the IL-6 path-
way [1,4,18]. These include monoclonal antibodies
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that target IL-6 (e.g. clazakizumab, olokizumab, siru-
kumab, siltuximab, ziltivekimab) or prevent IL-6
binding to the cognate IL-6 receptor (e.g. tocilizu-
mab, sarilumab), and Janus kinase inhibitors such as
tofacitinib [1–7]. For instance, the failure of anti-IL-
6 therapy in inflammatory bowel diseases is often
cited as an example of IL-6 functional complexity.
Here, its immunomodulatory activities are weighted
against its contribution to the maintenance of barrier
integrity in epithelial tissues [1,4]. IL-6 is also essen-
tial for the regulation of lipid, glucose and iron
metabolism, and is integral to the control of mito-
chondrial bioactivity [1,2,4,18]. These activities
impact processes affecting appetite, fatigue and
energy expenditure. For example, IL-6 reduces appe-
tite, delays gastric emptying and regulates postpran-
dial glycaemia and adiposity [18–20]. High
cholesterol, increased serum levels of high-density
lipoprotein (HDL), and weight gain, are all reported
consequences of tocilizumab intervention [1,2,4,21].
However, IL-6 antagonism changes the lipid compo-
sition to lower cholesterol-associated proatherogenic
factors, such as HDL-associated serum amyloid-A
and secretory phospholipase-A2 [21,22]. Similar stud-
ies also identify prominent roles for IL-6 in pain
perception, psychological well-being, the regulation
of haematopoiesis, and processes affecting tissue
turnover, regeneration and repair [8,18,23–26]. How
IL-6 signalling intermediates converge to regulate
these homeostatic processes while at the same time
supporting host defence and the response to tissue
damage is unclear. These uncertainties have compli-
cated the use of IL-6 targeting therapeutics in infec-
tious diseases including bacterial peritonitis, sepsis
and the recent COVID-19 public health emergency
[27].
Significantly, studies in drosophila and mice re-
affirm the dynamic and pleiotropic properties of IL-6
in physiology and pathophysiology [28]. Here, the
application of cytokine and cytokine receptor-deficient
mice, genetic knock-in strains and pharmaceutical
agents (e.g. antibodies, soluble receptors and engi-
neered fusion proteins) have helped to frame the
involvement of IL-6 in health and disease [1,2,4,29–
31]. While these studies have pioneered the develop-
ment of biological drugs routinely used in clinical
practice to inhibit IL-6, they have also identified the
mechanistic involvement of IL-6 signalling in exercise,
pain, anhedonia, appetite, metabolism and tissue
homeostasis [18]. Thus, the biological activities of IL-6
are highly conserved across species and experimental
model systems provide exciting opportunities to under-
standing the signalling basis of IL-6.
The IL-6 signalling cassette
Almost all stromal cells (e.g. endothelial cells, fibrob-
lasts) and certain subsets of immune cells (e.g. macro-
phages and other monocytic cells) produce IL-6 in
response to Toll-like receptor agonists, cytokines (e.g.
TNFa, IL-1b, IL-17, GM-CSF), lipid mediators (e.g.
prostaglandins), adipokines, and as a consequence of
cellular stress. Significantly, IL-6 gene expression is
subject to both homeostatic control and rapid induc-
tion following inflammatory challenge as a response to
infection, trauma, autoimmunity or cancer. These
involvements are equally reflected by the definition of
IL-6 as an adipokine, myokine, neurotrophic factor,
lymphokine and monokine. How IL-6 coordinates
each of the activities is subjected to much research,
and the complex nature of IL-6 biology is highlighted
by the various signalling mechanisms adopted by cells
to sense and interpret changes in IL-6 bioactivity (as
discussed below).
IL-6 signals through at least three distinct mecha-
nisms termed classical IL-6R signalling, IL-6 trans-
signaling and IL-6 trans-presentation (Fig. 1) [4]. The
classical signalling cascade begins when IL-6 binds the
cognate IL-6 receptor (IL-6R; also known as CD126).
The IL-6R represents a type-1 cytokine receptor and
as the a-subunit of the IL-6 receptor complex it is
responsible for sensing changes in IL-6 bioactivity [32–
34]. IL-6R is non-signalling by nature [32–34]. Once
engaged by IL-6, the IL-6R complexes with gp130,
triggering receptor oligomerization and formation of a
functioning receptor complex composed of two IL-6-
IL-6R-gp130 trimers (Fig. 1) [34–38]. Two gp130
molecules engage with one another in an interlocking
structure wherein each gp130 molecule contacts two
molecules of IL-6 via separate interfaces [39–41].
Receptor cross-linking renders gp130 signalling compe-
tent through a conformational change that allows
Janus kinases (namely Jak1, Jak2 and Tyk2) to catal-
yse the phosphorylation of tyrosine residues within the
cytoplasmic domains of gp130 [4,31–33]. These sites
act as docking regions for the STAT transcription fac-
tors STAT1, STAT3 and to a lesser extent STAT5
[32,33,42–44]. This activates the phosphorylation-
induced dimerization of previously latent STAT tran-
scription factors, which translocate to the nucleus to
exert their regulatory functions on gene expression
[45]. Beyond the regulation of Jak-STAT signalling,
gp130 also transmits signals through the SHP2 cascade
[32,33,46].
This receptor system is elegantly poised to contain
or limit the level of IL-6 receptor signalling. Here, var-
ious mechanisms have evolved to restrain gp130-
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mediated outcomes. For example, regulatory processes
that affect receptor internalization and deactivation
and signalling intermediates that inhibit or modify the
signalling output of IL-6. Many will be discussed in
due course, but include protein tyrosine phosphatases
(PTPs), microRNA (miR) that target mRNAs encod-
ing components of the IL-6 receptor cassette, and
STAT-inducible factors that act as negative feedback
inhibitors of gp130 signalling (e.g. PIAS, SOCS1, and
SOCS3) [45–48]. Thus, a wide range of intracellular
processes manage the way IL-6 signals are sensed and
interpreted by cells. However, before delving into these
processes, we must first consider the extracellular
events governing IL-6 bioavailability and bioactivity.
IL-6 bioactivity and bioavailability
Although gp130 was initially identified as the signalling
subunit of the IL-6 receptor complex, this glycoprotein
displays a broad pattern of cellular expression and
functions as the b-cytokine receptor for IL-11, IL-27,
oncostatin-M, ciliary neurotrophic factor, leukaemia
inhibitory factor, cardiotrophin-1 and cardiotrophin-
like cytokine [3,4,29]. Mice lacking gp130 (also referred
to as Il6st) are embryonically lethal with genetic muta-
tion studies identifying essential roles for gp130 in
development, haematopoiesis, tissue homeostasis, cell
survival and growth, and immune regulation [3,29]. In
contrast, IL-6R expression is more restricted and con-
fined to leukocytes, hepatocytes, megakaryocytes and
some mesenchymal populations [3,29]. As a conse-
quence, it is often challenging to understand how IL-6
delivers its full repertoire of biological activities. This
significantly changed with the discovery of a soluble IL-
6R (sIL-6R) in human urine and plasma [49,50]. IL-6
binds sIL-6R to form an agonistic complex capable of
triggering gp130 signalling (termed IL-6 trans-
signalling) [29,49–51]. Sharing sequence identity with
IL-12p40 and EBI3, the IL-6-sIL-6R complex resembles
a heterodimeric cytokine (akin to IL-12, IL-23, IL-27)
Fig. 1. Modes of IL-6 signalling and determinants of IL-6 responsiveness. The boxed cartoon representations show the three modes of IL-6
receptor signalling. Subunits of the cytokine receptor cassette are colour coded as indicated. PM denotes plasma membrane, and shows the
subunits bound to the cell surface in each signalling mode. The wider panel shows how the signalling intermediates associated with IL-6 receptor
signalling engage with gp130 (tyrosine residues based on the human gp130 sequence are designated) and contribute to the cellular activities of IL-
6. Note, the expression of STAT-inducible negative feedback inhibitors, which act to limit the protracted activation of the receptor complex.
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that is capable of broadening the types of cells that are
responsive to IL-6 [52,53]. The current view is that IL-6
trans-signalling primarily shapes immune responses
essential for host defence and processes affecting tissue
injury or pathology, whereas classical IL-6R signalling
coordinates the more physiological aspects of IL-6
bioactivity [3,4,29,30]. This paradigm is supported by
extensive experiments in murine models of inflamma-
tion using soluble gp130 (sgp130), a pathway inhibitor
with specificity for IL-6 trans-signalling and IL-11
trans-signalling [1–3,29,54,55]. For example, transgenic
mice over-expressing sgp130 are protected from acute
inflammatory challenge [56].
In human serum, sgp130 is present at saturating
levels (100–400 ngmL1) where it constitutes an IL-6
buffering system that prevents penetrance of minor
fluctuations in IL-6 concentration being interpreted as
a danger signal [1,2]. These potential systemic conse-
quences of IL-6 trans-signalling may explain the need
for a third mode of signal transduction [2,57,58]. IL-6
trans-presentation (also termed cluster signalling)
describes the initiation of signalling resulting from cell-
cell interactions between IL-6R-expressing antigen pre-
senting cells and gp130 on T cells [2,58]. IL-6-IL-6R
complexes are generated intracellularly by dendritic
cells and presented on the cell surface to gp130-
expressing T cells. This juxtacrine-type interaction
drives STAT3 signalling and Th17 polarization. This
process is critical for Th17 mediated inflammation of
the central nervous system in murine experimental
autoimmune encephalomyelitis [58]. Although the
pathological implications of IL-6 trans-presentation
are yet to established in humans, it is expected to be
refractory to anti-IL-6R targeting biologics and may,
therefore, represent a novel opportunity for blockade
of IL-6 activities [2,30].
The coordination of these modes of IL-6 receptor
signalling is influenced by changes in the bioavailabil-
ity of IL-6, sIL-6R and sgp130. IL-6 expression is
tightly regulated at the transcriptional level to ensure
physiological fluctuations in IL-6 during homeostasis
and rapid induction during infection, trauma or injury
[1,18]. In humans, circulating IL-6 levels remain low
(1–5 pgmL1), but these concentrations oscillate dur-
ing the course of the day and are equally subject to
seasonal variations between summer and winter
months [59–64]. Following immune activation, serum
IL-6 levels are rapidly increased (frequently reaching
ngmL1 or lgmL1 quantities) in response to cytoki-
nes, Toll-like receptor agonists, prostaglandins and
other stress signals [1,4,65]. Here, certain miR (e.g.
Let-7a), ribonucleases (e.g. regnase-1) and other RNA-
binding factors (e.g. Lin28B, Arid5a) function to
regulate IL-6 gene expression [1]. At the genetic level,
various single nucleotide polymorphisms (SNPs) affect
the bioactivity or bioavailability of IL-6 [66–68]. For
example, rs1800795, resulting in a G-to-C mutation in
the transcriptional promoter of the IL-6 gene causes
alterations in IL6 expression [69,70]. Carriers of this
mutation display increased risk for coronary heart dis-
ease, idiopathic juvenile arthritis and other forms of
inflammatory disease [70–72]. Similar phenotypic traits
are also seen in individuals with either IL6R or IL6ST
polymorphisms [73,74]. Individuals carrying the IL6R
polymorphism rs2228145 show enhanced sIL-6R and
IL-6 levels, reduced C-reactive protein and a lower risk
of cardiovascular disease [75,76]. Conversely, these
individuals show protection against SARS-CoV-2 dis-
ease and present with a reduced likelihood of hospital-
ization as a consequence of severe infection [27,68,77].
A challenge for IL-6 researchers is to understand
the dynamics and kinetics of IL-6 bioactivity. For
example, what is the physiological role for classical IL-
6R signalling versus IL-6 trans-signalling and IL-6
trans-presentation? Whilst research of IL-6 trans-
presentation is required, much work has centred on
the distinction between classical IL-6R signalling and
IL-6 trans-signalling. Here, the application of sgp130
has provided considerable evidence that IL-6 trans-
signalling broadens the types of cells that become IL-6
responsive (e.g. endothelial cells, fibroblasts, mesothe-
lial cells, smooth muscle cells). The inflammatory regu-
lation of sIL-6R supporting a role for IL-6 trans-
signalling in coordinating immune responses to dis-
ease. Classical IL-6R signalling is, however, linked
with the maintenance of immune or tissue homeostasis
(e.g. regulation of the acute phase response, tissue
regeneration, some metabolic processes). However,
these distinctions are not unequivocal. For instance,
classical IL-6R signalling supports the expansion of
IL-17-secreting CD4+ T-helper cells, with sIL-6R serv-
ing to retain circulating levels of IL-6. Thus, there are
shades of grey here, and the overall biological activity
of IL-6 is likely shaped differently in health and dis-
ease or different tissue compartments.
In the subsequent sections, we will now turn our
attention to the intracellular mechanisms that influence
the transmission of IL-6 receptor signals from the cell
membrane to the nucleus and affect the biological
properties of IL-6.
The complexities linked to Jak-STAT
signalling
The signalling pathways associated with IL-6 signalling
are discussed at length in the literature [1,4,31,32].
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However, it is acknowledged that context is key to
understanding IL-6 signalling outcomes. This has been
evidenced in models of bacterial peritonitis, a rare
complication of peritoneal dialysis in patients with
end-stage renal failure [78]. Intraperitoneal administra-
tion of a patient derived isolate of Staphylococcus epi-
dermidis in mice revealed that IL-6 acting on
surrounding stromal tissue initiates the recruitment of
leukocytes into the inflamed peritoneum by inducing
the expression of chemokines, cell adhesion molecules,
acute-phase-reactants and processes related to tissue
barrier permeability [79–83]. Here, IL-6 is generated
locally as a response to infection through the activa-
tion of stromal peritoneal cells (e.g. mesothelial cells)
and resident mononuclear cells. However, this initial
burst of IL-6 requires an early influx of infiltrating
neutrophils, which shed IL-6R to promote IL-6 trans-
signalling [84]. The release of sIL-6R from the neu-
trophil cell surface promotes the IL-6 regulation of
genes linked to the control of neutrophil effector func-
tion, bacterial clearance and the resolution of acute
inflammation [85–88]. Subsequent, repeated bouts of
inflammation distort this IL-6 response and recurrent
episodes of peritonitis promotes tissue remodelling and
peritoneal fibrosis [83,89,90]. In this scenario, IL-6
drives the proliferative expansion and retention of pro-
fibrotic interferon-c secreting CD4+ T cells within the
local tissue [89]. This illustrative example showcases
how IL-6 responses adapt to changes in inflammation
and emphasizes how IL-6, working within a cytokine
network, steers very different biological outcomes.
A key question is how IL-6 family cytokines, sharing
the same signal transducing subunit (namely gp130),
can elicit unique STAT activation profiles and func-
tional outputs. One explanation is likely to be found at
the membrane interface of the cytokine-receptor sig-
nalling complex. Here, our understanding rests on
Cryo-EM reconstruction of the extracellular region of
the IL-6-IL-6R-gp130 hexamer [39]. Less clear, is how
cytoplasmic portions of gp130 respond to receptor
cross-linking in partnership with different cytokine
receptors and how these elicit different profiles of STAT
transcription factor activation [36,39,45,91]. We con-
sider the example of IL-6 and IL-27. Both cytokines
engage specific receptors (IL-6R and IL-27R) in part-
nership with gp130, but activate STAT1 and STAT3 to
varying degrees, with different consequences [1,92]. This
is exemplified by observations in rheumatoid arthritis
where the pro-inflammatory role of IL-6 contrasts with
the more nuanced contribution of IL-27, which inhibits
the formation of ectopic lymphoid structures within the
inflamed synovium [93]. Similar studies in T cells
emphasize the opposing functions of IL-6 and IL-27 in
determining the effector characteristics of CD4+ T cells
[92–96]. At least in part, these differences are attributa-
ble to structural and sequence differences between the
cytokine receptors. For example, mutation of tyrosine
at position 613 to phenylalanine (Y613F) in the IL-27
receptor cytoplasmic side chain enforces an IL-6-like
STAT3 dominated phospho-STAT response [97]. The
Y613 residue serving as an additional docking site for
STAT1. Time course analysis of IL-27 signalling in Th1
polarized CD4+ T cells reveal that STAT1 activity con-
fers an interferon gene expression signature via an IRF1
feed-forward loop that is not seen in the transcriptional
profile of IL-6 [97]. Moreover, CD4+ T cells from
Stat1/ mice show that IL-6 and IL-27 induce very
similar transcriptional programmes [98,99]. Thus,
changes in the threshold of STAT1 activation results in
specific alterations in gene expression and includes
impacts on the control of certain STAT3-regulated
genes [98–101].
Alterations in the cytokine control of STAT tran-
scription factor phosphorylation have important con-
sequences at the gene level [45]. Studies employing
chromatin-immunoprecipitation in combination with
next-generation sequencing (ChIP-seq) demonstrate
how STAT transcription factors possess overlapping
but not identical binding profiles that are not limited
to canonical Gamma Activation Site (GAS)-like motifs
or Interferon-regulated STAT-responsive elements
(ISRE) [45,98,100,102]. These forms of genomic inter-
action or co-occupancy contribute to both transcrip-
tional cooperativity and the inhibition of gene
regulation [45,103–105]. It is also important to note
that regulatory mechanisms acting on the immediate
phosphorylation of STAT transcription factors also
shape the transcriptional output of IL-6.
The significance of these processes is evidenced as fol-
lows. Activated na€ıve CD4+ T cells isolated from Stat1/
 mice show increased STAT3 phosphorylation when
stimulated with IL-6 or IL-27, while the reverse is true
Stat3/ mice [98]. As a consequence, the STAT3 bind-
ing profile is increased in response to STAT1 deficiency,
and vice versa [98]. But what is the impact on gene regu-
lation? This question is not easy to address, particularly
as the relationship between STAT binding and gene regu-
lation is not simply a matter of gene induction [100].
Transcriptomic analysis of Stat3 deficient na€ıve CD4+ T
cells shows that an absence of STAT3 results in a col-
lapse in IL-6 and IL-27 gene regulation. In contrast,
Stat1 deficiency reduces the diversity of cytokine-induced
transcripts [98,100]. These findings are further supported
by studies in patients with STAT1 and STAT3 mutations
and have led to the conclusion that while STAT3 is the
principal driver of gene expression, STAT1 acts to fine-
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tune the transcriptional output of cytokines such as IL-6
and IL-27 [98]. Therefore, it is not merely differences in
phospho-STAT activation profiles, but the precise regu-
latory function of each STAT transcription factor that
determines cytokine-specific gene expression.
Fine tuning IL-6 responses and the
negative regulation of Jak-STAT
signals
Competition for phospho-tyrosine residues is not the
only contributing factor in determining the output of
Jak-STAT signals. This is because STAT transcription
factors are not thought to be present at saturating
levels in the cytoplasm [45]. Instead, various regulatory
mechanisms have evolved, which rate limit or fine-tune
the way cytokine cues are sensed and interpreted.
These include the steric hindrance of Jak activity, the
active identification of STAT transcription factors for
de-phosphorylation, and the post-transcriptional tar-
geting of cytokine mRNA [45]. For example, negative
feedback inhibitors (e.g. the Suppressor of Cytokine
Signalling protein family) that are induced by STAT
transcription factors to dampen activation of the sig-
nalling cassette [45,106]. Of these, SOCS3 is the best
characterized. SOCS3 was first identified as an IL-6
inducible pseudo-substrate that binds Jak2 to termi-
nate signalling [107]. SOCS3 binding centres on the
recognition of a short Glycine-Glutamine-Methionine
(GQM) motif on Jak2, which places SOCS3 in an ori-
entation that directly blocks kinase docking to gp130
[31,44,108,109]. This interaction prevents Jak binding
to a specific phospho-tyrosine residue with the gp130
sequence (identified at position 759 in man, and 757 in
mice) [32,46,47]. SOCS3 also inhibits Jak1, Jak2, and
Tyk2, but not Jak3, which lacks the GQM motif
[47,110]. However, it is the juxtaposition between Jak2
and gp130, that confers specificity of SOCS3 to IL-6
family cytokines [111] (Fig. 2). The biological reper-
cussions of SOCS3 inhibition have been evidenced in
studies in Socs3/ mice in vivo and patients lacking
functional STAT1 and STAT3 transcription factors
[47,110]. SOCS3 deficiency shifts the IL-6 regulated
transcriptome towards an IFNc-like STAT1-dominant
response [112]. Moreover, quantitative real-time PCR
analyses have confirmed altered SOCS3 transcript
abundance in peripheral blood mononuclear cells from
individuals with STAT1 gain-of-function and STAT3
loss-of-function mutations [113].
In addition to SOCS proteins, studies have shown
that protein phosphatases also regulate Jak-STAT
cytokine receptor signalling. Examples include dual
specificity protein phosphatases (DUSPs) and several
PTPs [45,114,115]. For instance, in the multiple mye-
loma cell line U266, CD45 (termed PTP receptor type
C; PTPRC) shapes the IL-6 control of cellular adhe-
sion and proliferation [116]. Significantly, these
enzymes act as biological rheostats of cytokine sig-
nalling and function to fine-tune the delivery or inter-
pretation of inflammatory cues. Notably, DUSP2
inhibits STAT3 activation and restricts the generation
of IL-17-secreting T-helper cells (Th17 cells) in
response to IL-6 and TGFb [114]. Conversely, PTPN2
and PTPN11 regulate the activities of STAT1 in
fibroblasts [117,118]. Whilst additional work is
required to explain the functional specificity and selec-
tivity of these enzymes for signalling intermediates
within the Jak-STAT cascade, studies suggest that
changes in the cellular expression of these phos-
phatases alter the cytokine responsiveness of a cell.
(A) (B)
Fig. 2. Relationship between STAT1 and STAT3 and IL-6
responsiveness. (A) Jak-STAT signalling in response to IL-6 triggers
activation of the latent transcription factors STAT1 and STAT3. The
dimerization and translocation of these proteins to the nucleus
targets genomic promoter and enhancer sites that include
consensus DNA motifs for STAT transcription factor binding (e.g.
IFN-stimulated responsive elements; ISRE, IFNc-activated
sequence; GAS). While STAT1 and STAT3 engage specific gene
targets, with STAT1 controlling various interferon-like responsive
genes (e.g. Irf1, Stat1 in CD4+ T cells) and STAT3 governing
responses linked with metabolism, proliferation, survival, and
functional identity. These often work at proximal and distal
promoter sites. Extending studies originating from investigations in
cancer, there is now increasing evidence supporting the role of
STAT1 in shaping the transcriptional output of STAT3. (B) The
balance of STAT1 and STAT3 activity is therefore instrumental in
determining the transcriptional output of IL-6 and regulatory
mechanisms, including the action of protein phosphatases act to
moderate or fine-tune the cell response to IL-6.
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For example, transcriptional profiling of T cells shows
that na€ıve CD4+ T-cell activation increases the expres-
sion of several protein phosphatases, including
PTPN2, PTPN22 and DUSP2. Thus, the transcrip-
tional output of a cytokine maybe altered by changes
in the expression of these enzymes. Studies have shown
that na€ıve CD4+ T-cell activation impairs the IL-6
control of STAT1 in activated and memory CD4+ T-
cell subsets [83,100,119,120]. This response is regulated
by increases in the expression of PTPN2 (and to a les-
ser extent PTPN22) following T-cell receptor activa-
tion [100]. Finally, the IL-6 inducible RNase Regnase-
1 targets the poly-adenylation tail of IL6 mRNA as
part of a post-transcriptional negative feedback mech-
anism. Significantly, mice lacking the Regnase-1
encoding gene (Zc3h12a) die prematurely of systemic
auto-inflammatory complications [121]. The physiolog-
ical importance of these mechanisms is emphasised by
a study showing that combined CRISPR targeting of
SOCS1, PTPN2, and Z3CH12A, synergistically poten-
tiates the anti-tumour efficacy of CD8+ T cells by pro-
moting effector memory T-cell functions [122].
MicroRNAs and their influence on IL-6
receptor signals
Various miR interfere with the IL-6 signalling cassette.
These regulatory elements fine-tune the expression and
bioavailability of specific components within the
receptor system and Jak-STAT pathway (Fig. 3).
However, there is little evidence of direct targeting of
IL-6 by miR, due to the short 30 untranslated region
(30 UTR) of the IL6 transcript. The most compelling
are miR-98 and miR-223 [123–126]. In systemic lupus
erythematous patients, a decrease in miR-98 was nega-
tively correlated with IL-6 expression in peripheral
blood mononuclear cells [123]. IL-6 is also regulated
by miR-223. Studies in an animal model of excessive
alcohol consumption show that IL-6 expression is
enhanced in miR-223/ mice and contributes to exac-
erbated ethanol-induced hepatic injury through an in
increase in neutrophil infiltration and reactive oxygen
species generation [125]. A similar phenotype is also
seen in skeletal muscle from miR-223/ mice where
miR-233 deficiency causes impaired muscle regenera-
tion and increases in interstitial fibrosis due to the
maintenance of a pro-inflammatory macrophage popu-
lation [124]. However, the miR-223 binding site within
the 30 UTR of IL-6 is not conserved in humans [127],
which raises the question of relevance to disease.
Several miR target components of the IL-6 receptor
complex or signalling intermediates within the down-
stream Jak-STAT pathway. For example, miR-34 and
miR-218, which are identified as tumour suppressors
[128,129]. Critically, miR-34a/ mice show an
increased incidence of colitis-associated intestinal
tumours that are typically larger in size and character-
ized by increases in IL-6R expression and STAT3
Fig. 3. MicroRNA targeting of the IL-6
receptor cassette. MicroRNAs with
selectivity for components of the IL-6
receptor and downstream signalling
intermediates are shown. The dashed
lines identify a potential influence on
sIL-6R bioavailability through the control of
IL-6R.
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activity [128]. These findings led to the development of
a liposomal miR-34a mimic (MRX34) for the treat-
ment of cancer patients with solid tumours [130].
However, the Phase-I clinical trials were terminated
due to serious immune-mediated adverse events result-
ing in four patient deaths [130]. Several other miR
have been shown to target STAT3 (e.g. miR-17, miR-
20a, miR-124, miR-125a, miR-223) [131–134]. With
activities controlling the pro-tumorigenic properties of
the IL-6 cytokine family, STAT3 drives various onco-
genic processes affecting cell cycle progression and sur-
vival, angiogenesis, tumour invasion and metastasis
[4]. In gliomas, STAT3 is a critical determinant of
tumour associated immunosuppression and shows a
negative correlation with miR-124. Adoptive transfer
of genetically engineered T cells expressing miR-124
dampened STAT3 activity and enhanced anti-tumour
immunity [132].
The negative regulators of the Jak-STAT cascade
are also subject to miR-mediated repression. miR-155
and miR-19 have been shown to target SOCS1 and
SOCS3, respectively [135,136]. In peritoneal macro-
phages, miR-155 repression of SOCS1 enhanced
interferon-mediated anti-viral immunity [135]. In gas-
tric cancer, PIAS3 was shown to be repressed by miR-
18a, leading to increased expression of STAT3 tran-
scriptional targets, such as BCL2L1 and MYC [137].
Lastly, miR-448 repression of PTPN2 has been associ-
ated with Th17 cell differentiation in cerebrospinal flu-
ids and blood mononuclear cells from patients with
multiple sclerosis [138].
Enhancer elements dictate the
transcriptional output of IL-6
STAT transcription factors rarely bind at gene pro-
moter regions. More frequently, STAT binding occurs
at intron-localized motifs, sometimes intergenic
regions, and often in close alignment with distal
enhancer elements [45,100,139,140]. Once thought to
be relatively static determinants of cell lineages, enhan-
cers are now appreciated to be dynamic regulators of
gene expression that exhibit a high degree of plasticity
through acetylation and deacetylation-based mecha-
nisms [102,141–143]. Central to this plasticity, the his-
tone acetyl transferase P300 (also termed CREB-
binding protein) is present at virtually all enhancers
where it mediates transcription initiation at nearby
promoters through the acetylation-dependent recruit-
ment of the transcription pre-initiation complex and
RNA polymerase II [142]. STAT transcription factor
interactions with P300 are a well-documented facet of
the immune response where they promote H3K27
acetylation and enhancer activation
[45,100,139,140,144–147]. In a cytokine signalling con-
text, regions of STAT-P300 co-occupancy may be
viewed as sites of signal integration. For example, the
generation of Th17 cells requires both IL-6 and IL-23
signalling, which combine to drive STAT3 and
BLIMP-1 binding to P300 enhancers at genes identify-
ing a Th17 cell lineage [139,144,148]. A similar sce-
nario is also seen in interferon-c-secreting CD4+ T
cells (Th1 cells) and IL-4-secreting CD4+ T cells (Th2
cells) where the localization of STAT4 and STAT6 to
P300 enhancers promote the expression of the lineage
defining transcription factors TBET and GATA3,
respectively [139]. Thus, the interaction of STAT tran-
scription factors with P300 sites shapes the effector
properties and lineage fate of immune cells, including
memory T-cell subsets, macrophages and innate lym-
phoid cells [100,139,140,144,148–150].
Various biochemical studies have explored the inter-
action of STAT transcription factors with P300
[147,151–153]. In vitro, STAT1 binding to P300 trig-
gers a trans-auto-acetylation reaction, which catalyses
the recruitment and activation of neighbouring P300
molecules. Here, the phosphorylation-induced dimer-
ization of the STAT1 transcription factor complex is
important for bridging P300 molecules and drawing
them into proximity with one another [147]. The crys-
tallographic analysis of P300 identifies that these inter-
actions are facilitated through acetylation reactions at
functionally relevant domains within the autoin-
hibitory loop of P300 [147,152]. These protein modifi-
cations contribute to the dynamic auto-regulation of
P300 activity when in proximity with activated STAT
transcription factors [153]. This mechanism is transfer-
able to other transcription factors (e.g. interferon
responsive factors; IRF) [147].
Advances in next-generation sequencing technolo-
gies (e.g. ChIP-seq, ATAC-seq and Hi-C sequencing)
are now affording exciting opportunities to under-
stand how STAT transcription factors function in
cooperation or competition at promoter sites (e.g.
through cross-regulation), and form meaningful part-
nerships with other transcription factors at enhancers.
Here, in silico motif enrichment analyses and bio-
chemical approaches support the idea that STAT
transcription factors engage with highly dynamic
enhancer interactomes in a context-dependent manner
[100,140,147,154]. Thus, STAT proteins also perform
scaffolding functions essential for the development of
new enhancer architectures following stimulation.
Nonetheless, further work is required to understand
the spatial organization of STAT transcription factors
within active chromatin regions.
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ChIP-seq and ATAC-seq have evidenced the
dynamic and complex nature of STAT transcription
factor interactions with the genome (e.g. P300 sites as
discussed) [45,100,139,140,144,150]. These technologies
have also identified the interaction of STAT transcrip-
tion factors with latent enhancers, which are exposed
following prior immune challenge with cytokines,
pathogen-associated molecular patterns, or damage-
associated molecular patterns [102]. Studies of macro-
phages stimulated in vitro have shown that the latent
enhancer repertoire is ligand-specific, delivering over-
lapping and distinct chromatin remodelling in response
to different TLR ligands (CpG, MALP2, LPS) and
cytokines (TNFa, IL-1b, TGFb, IFNc) [102]. Latent
enhancers are therefore sites of cytokine and TLR
cross-regulation with the potential to make nuanced
contributions to inflammatory responses in the com-
plex environment of tissue inflammation where numer-
ous ligands act in concert. These forms of interaction
may be relevant to cooperation seen between IL-6/
gp130 signalling and TLR2 and TLR4 in gastric
tumours and models of septic shock [108,155–158].
Once exposed, these latent enhancers remain poised or
active for some time [102,149]. Latent enhancers are
therefore described as a type of innate immune mem-
ory, which, unlike adaptive-immune memory, precon-
ditions cells for challenges they are yet to encounter
[159]. Consequently, these enhancer sites might impact
the stromal tissue response to infection, trauma or
injury, and contribute to the development of
inflammation-induced tissue damage and chronic dis-
ease progression. Thus, genomic imprinting through
enhancer re-organization may contribute to a ‘genomic
memory’ of a prior environmental stimulus. Here, it
will be important to combine studies of genomic archi-
tecture with investigations of how cytokines like IL-6
shape the proteome following inflammatory stimula-
tion [97]. To understand this relationship, it is essential
to identify the nature of these latent enhancers.
An emerging literature points to a subset of Alu ele-
ments functioning as either tissue-specialized (poised/
primed) or latent enhancers [160–163]. Alu elements
belong to a family of endogenous retroelements, which
comprise up to 10% of the human genome and are
often transcriptionally repressed through methylation
[161,164]. One study employed meta-analyses of multi-
ple publicly available genomics datasets to assess Alu
enhancer function across tissues. This analysis identi-
fied involvements in processes integral to tissue spe-
cialization. These included neuronal involvement in
the brain, immunological processes in the spleen, and
metabolism in the Liver [160]. This functional analysis
is supported by the highly tissue-specific distribution
of the ‘poised’ enhancer marker H3K4me1 at a subset
of Alu elements with P300 occupancy. Thus, reflecting
a proximity to genes controlling tissue identity [161].
These results are somewhat similar to functional char-
acteristics of super-enhancers, which were originally
described as determinants of cell identity in terminally
differentiated cells [141,143]. Elsewhere, in a model of
serum-withdrawal, previously latent Alu enhancers
were shown to promote cellular proliferation by regu-
lating chromatin looping through interactions between
RNA Polymerase III, general transcription factor III
(TFIIIC), CCCTC-binding factor (CTCF) and the
cohesion complex [163]. Rather than acting in cis, Alu
enhancers appear to govern the overall chromatin
architecture influencing gene expression over long dis-
tances through the organization of three-dimensional
units of gene regulation termed topologically associ-
ated domains [161,163]. Although this is yet to be
investigated in an inflammation context, a role in
coordinating higher-order chromatin structure would
fit neatly with the non-linear relationship between
intensity of cytokine-receptor interaction, STAT tran-
scription factor binding, and fold change in gene
expression [100,165]. Here, a potential link to the biol-
ogy of STAT transcription factors is identified by
the link between Alu elements and various
interferonopathy-like conditions [166–168]. We can,
therefore, hypothesize that STAT transcription factor
binding to Alu enhancer may coordinate de novo geno-
mic architectures that facilitate adaptation to immune
challenge. Further work is, however, required to char-
acterize the definition of latent enhancers that are
unveiled following exposure to immune or environ-
mental challenge.
In summary, in silico motif enrichment analyses are
supportive of the notion that STAT transcription fac-
tors form unique complexes in a highly context-
dependent manner [140]. Thus, while poised enhancers
contain consensus sequences for STAT transcription
factor binding, STAT-linked latent enhancers are
enriched for adenosine-rich IRF binding sites [102].
For example, Alu enhancers are notable for their par-
ticularly high density of transcription factor binding
motifs with at least one study proposing that evolu-
tionary divergence has created Alu subsets that har-
bour distinct sets of concensus motifs [161]. Analysis
of Encode deposited ChIP-seq experiments has demon-
strated binding of AP-1 subunits (FOS, JUN, JUNB,
JUND, FOSL1), SP-1, GATA-1, SMADs, and the
chromosome looping co-factor CTCF [160]. Other
studies identify binding factors such as activity-
dependent neuroprotective protein, which bind almost
exclusively to Alu enhancers [163].
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Relevance to IL-6-driven pathology
Genetic ablation studies in mice showcase roles for IL-
6 in both normal physiology and pathophysiology.
These are often recapitulated in humans where biologi-
cal drugs and small molecule inhibitors acting directly
on the IL-6 cytokine receptor or downstream sig-
nalling intermediates identify the importance of IL-6
signalling through STAT1 and STAT3 [169–173].
The Jak-STAT pathway has evolved to sense and
interpret cytokine cues essential for cellular prolifera-
tion and functional identity [171]. These include activi-
ties controlling the maintenance of tissue homeostasis
and host immunity against infection, autoimmunity
and cancer [169]. As discussed, patients with genetic
mutations affecting Jak-STAT signalling display vari-
ous immune deficiencies and biological drugs and
small molecule inhibitors commonly prescribed in vari-
ous disease settings often target STAT-activating
cytokines (e.g. or Jak activation) [1,169,171]. So, how
does IL-6 signalling through the Jak-STAT pathway
shape the course of the disease?
The transcriptional output delivered by the Jak-
STAT pathway is highly dynamic and incorporates
partnerships with other transcription factors [45].
Working at transcriptionally relevant promoters or
enhancers (as discussed earlier), these networks inter-
pret cytokine cues responsible for disease progression.
Here, gene regulation is often affected by a transcrip-
tional interplay between individual STAT transcription
factors (termed cross-regulation) [45,48,101,174,175].
For example, STAT1-activating cytokines show
enhanced STAT3 responses in cells lacking STAT1
(and vice versa) [45]. Cross-regulation is particularly
evident in cancer cells where the deletion of STAT1 or
STAT3 alters the expression of genes controlling
tumour expansion and proliferative survival [48,91].
While these genetic ablation studies illustrate how
changes in STAT1 and STAT3 signals impact the fate
or functional properties of a cell, the physiological
processes steering cross-regulation are unknown. How-
ever, these interactions may account for changes in
leukocyte effector functions, the clinical presentation
of pathology, and response to drug therapy. To con-
textualize the potential relevance of these mechanisms
to disease, we draw on emerging literature from stud-
ies of rheumatoid arthritis and other autoimmune con-
ditions (Fig. 4).
In mouse models of experimental autoimmune or
inflammatory disease, IL-6 deficiency often limits the
histological signs of pathology. For example, hallmarks
of synovial hyperplasia, synovial infiltration (or associ-
ated exudate), and joint erosion are all less pronounced
in Il6/ mice with arthritis [176–179]. These outcomes
reflect the impact of IL-6 on cellular proliferation, the
expression of chemokines, adhesion molecules and
degradative enzymes, and bone turnover [180–182].
Despite the high concentration of IL-6 in serum and
synovial fluids of patients with arthritides, structural
cells within the joint (e.g. chondrocytes, synoviocytes,
fibroblasts, endothelial cells and activated infiltrating
leukocytes) lack IL-6R expression [100,178,183,184]. In
this regard, increases in synovial sIL-6R correlate with
extensive joint destruction and correspond with more
advanced stages of rheumatoid arthritis [185,186]. Thus,
many of the biological outcomes associated with IL-6
in synovitis are transmitted by IL-6 trans-signalling and
require activation of the Jak-STAT pathway and the
latent transcription factor STAT3 [178,184,187–189].
The Jak-STAT pathway senses and interprets cytokine
cues targeted by drugs (e.g. tocilizumab, tofacitinib) com-
monly prescribed for the treatment of rheumatoid arthri-
tis [1,4,45,169–171]. As part of their mode-of-action, these
inhibitors block cytokine signals elicited by STAT1 and
STAT3 transcription factors [1,169,171]. In murine mod-
els, STAT1 activities often reduce arthritis severity [189–
Fig. 4. The complexities of IL-6 biology in
immune-mediated disease. A summary of
IL-6 involvements in immune-mediated
inflammatory disease. Using rheumatoid
arthritis as an example, the figure
showcases the major contributions of IL-6
to systemic immune outcomes,
comorbidity, and reactions relevant to local
pathology in the inflamed joint.
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191], whereas STAT3 regulates leukocyte recruitment and
activation, synovial hyperplasia and joint erosion
[98,178,184,192–198]. Genetic ablation studies show that
STAT1 and STAT3 share a complex relationship, often
opposing each other [45,48,91,101]. For example, STAT1
shapes the transcriptional output of STAT3 in CD4+ T
cells (e.g. altering effector functions) [45,98,99,-
195,197,199,200]. Studies in gp130Y757F:Y757F mice with
antigen-induced arthritis provide some evidence of STAT
transcription factor cross-regulation [184,199,201]. These
animals possess a single tyrosine-to-phenylalanine substi-
tution in the cytoplasmic domain of gp130 that causes
a prolonged hyperactivation of STAT1 and STAT3
following cytokine activation [43,44,109,201]. Here,
gp130Y757F:Y757F mice with antigen-induced arthritis dis-
played exacerbated joint pathology with synovitis reveal-
ing evidence of lymphoid aggregates [184,199]. Moreover,
analysis of CD4+ T cells from inguinal draining lymph
nodes of gp130Y757F:Y757F mice with arthritis showed that
genetic ablation of Stat1 in these animals enhanced the
expression of several STAT3 regulated cytokines involved
in T cell-driven synovitis [199]. Identical results were also
observed in knock-in mouse strains whereby the gp130-
dependent STAT3 and SHP2 signals were disrupted by
replacing the mouse gp130 gene with human gp130
mutant cDNA (termed gp130Y759F:Y759F) [42,198,202,203].
The tyrosine residue at position 757 in mouse gp130 and
position 759 in human gp130 is a critical regulatory deter-
minant of gp130 signalling and is required for the recruit-
ment of SH2-domain containing cytoplasmic PTP SHP2
and the docking of SOCS3, which limits gp130-mediated
STAT transcription factor activation [46]. In this regard,
the genetic manipulation of SOCS3 activity in experimen-
tal models of arthritis often show similarities with the
pathological outcomes recorded in both gp130Y757F:Y757F
and gp130Y759F:Y759F mice [204–206].
Extending the investigation of STAT1 and STAT3
cytokine signalling to wild-type, Il6/ and Il27ra/
mice with antigen-induced arthritis, studies show that
these mice develop joint disease resembling the
heterogeneous features of synovitis commonly seen in
humans with rheumatoid arthritis [93,100,184,199,
207,208]. For example, Il6/ mice develop a low-
inflammatory pathology (lacking an immune cell infil-
trate) resembling fibroblast-rich synovitis [176–179,184,
188,207,208]. This pathology contrasts with that of
wild-type mice, which present with a diffuse inflamma-
tory infiltrate, and Il27ra/ mice where the presence
of organized ectopic lymphoid-like structures (ELS)
resembled lymphoid-rich synovitis [93,178,184,207–210].
Reflecting on these results, IL-6 and IL-27 regulate
STAT1 and STAT3 activities through receptor systems
containing gp130 [4,98,211]. However, IL-27 elicits a
stronger STAT1 response and often blocks STAT3-
driven outcomes [4,98,99,211]. Here, changes in the rel-
ative activation of STAT1 versus STAT3 may influence
immune cell effector function, the response of stromal
tissues to inflammation and activities that may alter
clinical outcomes or the course of disease. So, how are
these processes regulated?
As discussed, cytokine signalling via the Jak-STAT
pathway is controlled at multiple levels
[45,106,115,171]. These include negative feedback
mechanisms (e.g. SOCS proteins) induced by STAT
transcription factors to limit activation of the sig-
nalling cassette [45,106]. Others act on phosphoryla-
tion events immediately following cytokine receptor
engagement [45]. For example, PTPs involved in meta-
bolic and immune regulation. Activities associated
with these enzymes include control of kinases and
transcription factors in the Jak-STAT cascade
[45,100,115–117,212–214]. These include PTPN2 and
PTPN22, which often possess genetic traits associated
with increased susceptibility for autoimmunity [215].
Focussing on the biology of PTPN2 and PTPN22,
recent studies suggest that these regulatory enzymes
act as rheostats of Jak-STAT cytokine signalling and
re-tune the way cells respond to cytokine cues trans-
mitted by STAT1 and STAT3. Using CD4+ T cells
from Lck-Cre:Ptpn2fl/fl (T-cell restricted deletion) and
Ptpn22/ mice, PTPN2 and PTPN22 have been
reported to inhibit STAT1 tyrosine-phosphorylation
(pY-STAT1) in IL-6-treated effector memory CD4+ T
cells [100,216]. When compared to IL-6 responses in
na€ıve CD4+ T cells, this form of STAT1 regulation
altered the types of genes under STAT3 control in
memory CD4+ T cells [100]. In murine models,
PTPN2-deficiency exacerbates disease through activi-
ties on follicular T-helper cells, regulatory T cells and
B cells [216–222]. For example, Ptpn2+/ mice develop
synovitis showing enriched expression of synovial
Th17 cells and ELS in the SKG model of autoimmune
arthritis, consistent with the development of synovitis
in Il27ra/ mice with AIA [93,219]. Moreover, analy-
sis of IL-6-treated effector memory CD4+ T cells
showed that PTPN2 inhibition of pY-STAT1 enhances
STAT3 gene regulation through promoters displaying
P300 super-enhancer architectures [100,139]. These
included cytokines (IL-17A, IL-21), transcription factors
(Bcl6), checkpoint regulators (CD274) and chemokine
receptors (CXCR4, CXCR5) linked with lymphoid-rich
synovitis [100]. Here, analysis of PTPN2 in human syn-
ovial biopsies showed the highest expression in
lymphoid-rich synovitis [100]. Thus, PTPN2 contributes
to the control of Jak-STAT signalling in lymphocyte-
driven pathology affecting the composition, organization
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and activities of cells involved in ectopic lymphoneogen-
esis. In contrast, PTPN22 shows a more universal pat-
tern of expression in fibroblast-rich, myeloid-rich, and
lymphoid-rich forms of synovitis [100]. This may reflect
the role of PTPN22 in other hematopoietic populations
(e.g. myeloid cells) and stromal tissues, which includes
the inhibition of STAT1 signals in T cells, macrophages
and fibroblasts [100,139,214,218,223–228]. Collectively,
these data suggest that the interpretation of cytokine
cues sensed by a common receptor subunit (e.g. gp130)
are fine-tuned by PTP to direct alternate inflammatory
outcomes.
A key question is whether IL-6 utilizes different
enhancer subtypes to affect its homeostatic and disease-
causing properties. Latent enhancers, as an adaptive
response to environmental stimuli, might be expected to
drive processes relevant to supporting tissue adaptation.
Meanwhile, enhancers linked to IL-6 homeostatic prop-
erties are likely to be to be constitutively active as
homeostasis is ongoing under tonic signalling. Indeed,
genes contributing to set biological processes often
share common mechanisms of transcriptional control
[229]. Functional genomics offer support for this
hypothesis. For example, the initial description of latent
enhancers specifically referenced wound healing as an
enriched Gene Ontology term [102]. Moreover, there is
some evidence to support the role of specific enhancer
subtypes in human pathology. For example, regions of
high-density P300 binding, termed super-enhancers (or
stretch-enhancers), are disproportionately associated
with disease susceptibility loci compared with regular
enhancers [230]. In this regard, the Jak inhibitor tofaci-
tinib was found to alter the expression of genes com-
monly identified in genome-wide associated studies and
controlled by super-enhancers [139].
The connection between STAT transcription factors
and Alu enhancers is significant due to the historic
association of retroelements with SNPs linked to most
types of human pathology. For example, systemic lupus
erythematosus and Sj€orgren’s syndrome, and human
genetic disorders such as Aicardi-Goutieres syndrome
and familial chilblain lupus [166,167]. These diseases
are described as interferonopathies and are often asso-
ciated with altered STAT transcription factor responses
[167,168]. Thus, pathophysiology may arise through
changes in the interpretation of cytokine cues. This
might arise through several mechanisms, including
insertion-linked mutagenesis, Alu-RNA linked autoim-
munity, or interference with cellular processes including
ribosome function. Retroelements are not static, and
have the capacity, once expressed, to interfere with cel-
lular processes and in rare cases, reintegrate into the
genome [164]. Here, structural variations caused by Alu
insertions often contribute to hereditary disease, blood
disorders and neurological conditions. In inflammation,
Alu RNA expression is interferon inducible and has the
capacity to activate intracellular Pattern Recognition
Receptors including MDA5 and RIG-1 to further
propagate the immune response [231,232]. It has been
postulated that changes in Alu-RNA expression may
contribute to neuroinflammation and neurodegenera-
tion in Alzheimer’s disease, and the functional proper-
ties of peripheral blood cells isolated from patients with
Systemic Lupus Erythematous (SLE) [167,233]. Further
work is however required to extend the links between
genetic disease susceptibility, STAT transcription factor
involvement in these diseases, and the epigenetic mech-
anisms driving disease onset.
Conclusions and perspectives
Advances in cytokine biology increasingly identify novel
mechanisms of cytokine involvement in physiology and
pathophysiology. Studies in animal models and cell sys-
tems have now been aided by the widespread use of
cytokine targeting therapies in patients with complex
immune-mediated conditions, infectious diseases and
cancer. This is epitomized by studies of the Jak-STAT
pathway, which frequently combine methods common
to the evaluation of cellular immunology, histology,
functional genomics and the holistic analysis of the pro-
teome and transcriptome. These approaches provide a
high-level understanding of how cells and tissues sense
and interpret cytokine cues during health and disease.
Various challenges, however, still remain. Focussing on
the biology of IL-6, there is a pressing need to under-
stand how this major inflammatory cytokine contributes
to normal physiology, competent anti-microbial host
defence, and the transition to pathophysiology and sys-
temic chronic inflammation. Here, the estate agents (re-
altor) adage ‘Location, Location, Location’ takes on an
important meaning and offers opportunities to under-
stand how the systemic and local inflammatory context
is shaped to promote disease susceptibility, heterogene-
ity in patient pathology, multimorbidity and response to
drug therapy.
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